tirzepatide shortage update today FDA Says Compounded Must Exit the Market Mounjaro will remain off shortage

doi: 10.3389/fimmu.2022.853015 156 LaforgeM.ElbimC.FrreC.HmadiM.MassaudC.NussP.et al

Gradual and sustainable weight loss Tirzepatide has the potential to reduce body weight by 15-20%

Tirzepatide belongs to a groundbreaking class of medications known as dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et.al

1, Blue Cross Blue Shield and Point32Health, the owner of Harvard Pilgrim Health Care and Tufts Health Plan, said they will scale back their coverage of GLP-1s due to their increased popularity